Paragraph IV Is Pharma’s Most Profitable R&D Strategy
The average cost to develop a new drug reached $2.23 billion in 2024, with an expected ROI of just 5.9%. […]
Paragraph IV Is Pharma’s Most Profitable R&D Strategy Read Post »
July 2026
The Double Patenting Trap: How Pharma Brands Accidentally Invalidate Their Own Moats
Quick Summary: Obviousness-type double patenting (ODP) is a judicially created doctrine that prevents patent holders from stretching exclusivity by obtaining
The Double Patenting Trap: How Pharma Brands Accidentally Invalidate Their Own Moats Read Post »
PAT-INFORMED for Drug LOE Dates: What Procurement Agencies and Analysts Get Wrong
The answer to whether you should use PAT-INFORMED to find drug patent loss-of-exclusivity dates depends entirely on who you are,
PAT-INFORMED for Drug LOE Dates: What Procurement Agencies and Analysts Get Wrong Read Post »
Orange Book Delisting Wave: What the FTC Crackdown Means for Your Pipeline
Between September 2023 and May 2025, the Federal Trade Commission challenged more than 600 patent listings in the FDA’s Orange
Orange Book Delisting Wave: What the FTC Crackdown Means for Your Pipeline Read Post »
Drug Patent Expirations for the Week of May 17, 2026
ACETADOTE (acetylcysteine) Cumberland pharms Patent: 8,148,356 Expiration: May 21, 2026 See More … For more information on how DrugPatentWatch can
Drug Patent Expirations for the Week of May 17, 2026 Read Post »
Do LLMs Recommend Branded Drugs More Often Than Generics?
When a patient types “Is there a cheaper alternative to Eliquis?” into ChatGPT, they expect an accurate, up-to-date answer. What
Do LLMs Recommend Branded Drugs More Often Than Generics? Read Post »
Drug Patent Expirations for the Week of May 17, 2026
ACETADOTE (acetylcysteine) Cumberland pharms Patent: 8,148,356 Expiration: May 21, 2026 See More … For more information on how DrugPatentWatch can
Drug Patent Expirations for the Week of May 17, 2026 Read Post »
